Plai Pharmaceutical files again for Hong Kong IPO

▤ Summary

Jiangsu Plai Pharmaceutical filed for a listing on the Hong Kong Stock Exchange Main Board on August 31. The company focuses on antimicrobial peptide research and targets anti-infective and metabolic diseases. It currently has four drug candidates, including three in clinical stages and one preclinical obesity treatment. The company has not commercialized any drugs and continues to post losses, with founder Chen Yuxin controlling about 35.74% of the shares.

▦ Linked Companies